Akari Therapeutics, Plc
AKTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | upgrade | Hold →Buy | Jul 20, 2026 |
| Maxim Group | downgrade | Buy →Hold | Apr 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 5, 2022 |
| Alliance Global Partners | maintain | Buy | Nov 1, 2022 |
| B. Riley FBR | maintain | Buy | Mar 13, 2020 |
| B. Riley Securities | maintain | Buy | Mar 13, 2020 |
| B. Riley Securities | maintain | Buy | Mar 12, 2020 |
| B. Riley FBR | maintain | Neutral | May 5, 2018 |
| Canaccord Genuity | maintain | Buy | Mar 29, 2018 |
| B. Riley FBR | maintain | Neutral | Feb 8, 2018 |
| William Blair | upgrade | Market Perform →Outperform | Sep 22, 2017 |
| Chardan Capital | upgrade | Sell →Neutral | May 31, 2017 |
| William Blair | downgrade | Outperform →Market Perform | May 12, 2017 |
| William Blair | downgrade | Outperform →Perform | May 11, 2017 |
| Chardan Capital | maintain | Sell | Apr 17, 2017 |
| Chardan Capital | maintain | Sell | Jul 11, 2016 |
Earnings History
Next report: Dec 4, 2026 · EPS est. $-2.23| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-272.00 | $-1.04 | — | — |
| May 19, 2026 | $-9.74 | $-1.33 | — | — |
| Mar 30, 2026 | $-2.99 | $-1.80 | — | — |
| Nov 13, 2025 | $-4.00 | $-1.60 | — | — |
| Aug 13, 2025 | $-2.40 | $-3.60 | — | — |
| May 15, 2025 | $-5.40 | — | — | — |
| Apr 16, 2025 | $-6.80 | $-40.00 | — | — |
| Nov 19, 2024 | $-472.00 | $-0.60 | — | — |
News
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation
CEO Abizer Gaslightwala discusses Akari's novel PH1 payload strategy and execution priorities supporting AKTX-101's advancement toward planned Phase 1 clinical development in mid-2027
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value
Patent filing covers PH1 payload's unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 10,763 shares, a decline of 64.3% from the August 31st total of 30,117 shares. Based on an average trading volume of 101,607 shares,
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $9.65 and traded as high as $12.04. Akari Therapeutics shares last traded at $10.96, with a volume of 128,527 shares. Wall Street Analyst Weigh In Several
Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September
Video webcast now available here
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027